Anavex Life Sciences Corp. (NASDAQ:AVXL) has released positive data, from the pre-clinical study of ANAVEX 3-71. The results of the study show a significant decline in the rate of cognitive deficit of sigma-1. Anavex is a biopharmaceutical company, currently in its clinical stage, which focuses on the development of drugs for neurodegenerative diseases, CNS diseases and cancer therapies.

AVXL released the data, during the “14th International Symposium on Advances in Alzheimer’s Therapy”, held from March 9 to 12. The report identified that the company made use of aged transgenic rats and their response to the drug was observed. Added to this, the drug was also administered to wild rats, in the same amount, and the two results were then compared. The test subjects were mostly 12-14 months of age at the start of the experiment and were 18-20 months at the time of the cognitive tests.

Professor Claudio Cuello, the main author of the study, revealed that the study backs up the company’s belief that the drug can be utilized for the treatment of Alzheimer’s disease. He also clarified that the study focused on the long-term effects of the drug and also examined the effects of re-administering the drug after a 5-week break. The author also revealed that the study showed the development of anti-inflammatory properties in the rats, which he hoped would be observed in human patients as well.

Recently, Anavex had also made significant progress with another drug for Alzheimer’s disease. The company had successfully gained a permit to extend the phase-2a clinical trial of ANAVEX 2-73. The extension had initially been requested by the enrolled patients and their caregivers and was pending approval from the Ethics Committee in Australia. Participants who had taken the drug for 52-weeks would now be allowed to roll into part-B of the trial, extending the dosage period to 104-weeks. This would further strengthen the results from the study.

Anavex Life Sciences Corp. (NASDAQ:AVXL) had a trade volume of 1.35 million and lost 3.14% during the March 14 trading session, to close at a share price of $4.93.